Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

709
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
709
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

301
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
301
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

908
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
908
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

778
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
778
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

994
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
994
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

536
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
536

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice.

Gut microbes·2026
Same author

Correlation of Probe-Based Confocal Laser Endomicroscopy (pCLE) and Mucosal Integrity Testing (MIT) with Epithelial Barrier Function and Presence of Gastroesophageal Reflux Disease (GERD).

Digestive diseases and sciences·2021
Same author

Editorial: Stomach and duodenum.

Current opinion in gastroenterology·2020
Same author

Gastric Peptides-Gastrin and Somatostatin.

Comprehensive Physiology·2019
Same author

Editorial: Stomach and duodenum.

Current opinion in gastroenterology·2019
Same author

Proton pump inhibitors: placing putative adverse effects in proper perspective.

Current opinion in gastroenterology·2019

Related Experiment Video

Updated: Dec 10, 2025

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.1K

Proton pump inhibitors: misconceptions and proper prescribing practice.

Mitchell L Schubert1,2

  • 1Division of Gastroenterology, Department of Medicine, Virginia Commonwealth University Health System.

Current Opinion in Gastroenterology
|September 2, 2020
PubMed
Summary
This summary is machine-generated.

Concerns about proton pump inhibitor (PPI) side effects are widespread, but recent high-quality studies show most are unfounded. PPIs are safe when prescribed appropriately for valid medical indications.

More Related Videos

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.9K
Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
05:50

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care

Published on: September 22, 2023

4.0K

Related Experiment Videos

Last Updated: Dec 10, 2025

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.1K
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.9K
Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
05:50

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care

Published on: September 22, 2023

4.0K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Evidence-based medicine

Background:

  • Proton pump inhibitors (PPIs) are widely prescribed for acid-related gastrointestinal disorders.
  • Numerous epidemiological studies and meta-analyses have linked long-term PPI use to various adverse effects.
  • Public perception and prescriber confidence in PPI safety have been negatively impacted by these studies.

Purpose of the Study:

  • To review and contextualize recent literature on alleged adverse effects of proton pump inhibitors.
  • To assess the quality of evidence supporting claimed PPI-associated risks.
  • To provide guidance on the appropriate use of PPIs.

Main Methods:

  • Systematic review of the past year's literature on PPI adverse effects.
  • Critical appraisal of retrospective database studies and meta-analyses.
  • Inclusion of data from large-scale surveys and placebo-controlled trials.

Main Results:

  • The majority of purported serious adverse effects linked to PPIs lack robust supporting evidence.
  • Low-quality evidence from retrospective studies cannot establish causality.
  • Recent well-designed studies, including a placebo-controlled trial, indicate PPIs are generally safe, with a potential minor association with enteric infections.

Conclusions:

  • Most publicized serious adverse effects attributed to PPIs have been debunked by more rigorous research.
  • PPIs should be reserved for valid indications and used at the lowest effective dose for the shortest necessary duration.
  • Periodic reassessment of the need for long-term PPI therapy is recommended.